Pseudothrombus deposition accompanied with minimal change nephrotic syndrome and chronic kidney disease in a patient with Waldenström's macroglobulinemia: A case report

Table 1 Chemotherapy regimen

Chemotherapy cycle	Chemotherapy drugs used	Workups before chemotherapy	Workups after chemotherapy
First cycle; 3/5-17/5/2018	Bortezomib 2.5 mg, dexamethasone 20 mg, and thalidomide tablets 100 mg	CBC: WBC 7.03 × 109/L, Hb 114 g/L, PLT 360 × 109/L; LFT and RFT: Albumin 11.7 g/L, globulin 57.7 g/L, ALT and AST were normal, urea 10 mmol/L, creatinine 167.0 μmol/L, serum β-2 microglobulins; 2.54 mg/L; TFT: TSH 10.31 μIU/mL, FT3 2.11 pmol/L, FT4 7.7 pmol/L; Serum Igs: IgM > 66.42 g/L, IgG < 1.41 g/L, IgA, C3, and C4 were normal. ESR 114 mm/h; CRP < 5.00 mg/L; Urinalysis: Urine protein 2+, occult blood 1+, RBC count 181/μL, 24-h urine protein 1600.50 mg/24 h	CBC: WBC 26.37 × 109/L, Hb 104 g/L, PLT 112 × 109/L, neutrophils 9.8%; LFT and RFT: Albumin 24.9 g/L, globulin 47.5 g/L, ALT and AST were normal, urea 7.1 mmol/L, creatinine 118 μmol/L; ESR 123 mm/h; Serum Igs: IgM 44.66 g/L
Second cycle; 4/6-17/6/2018	Bortezomib 2.2 mg, dexamethasone 20 mg, and thalidomide tablets 100 mg	CBC: WBC 10.8 × 109/L, Hb 113 g/L, PLT 637 × 109/L; Urinalysis: Urine protein 1+; LFT and RFT: Albumin 30.1 g/L, globulin 33.8 g/L, ALT and AST were normal, urea 5.6 mmol/L, creatinine 112 μmol/L, serum β-2 microglobulins; 3.07 mg/L; Serum Igs: IgM 23.75 g/L, IgA 0.55 g/L, IgE was low; ESR 100 mm/h	CBC: WBC 24.2 × 109/L, neutrophils 83.7%, Hb 110 g/L, PLT 158 g/L; LFT and RFT: albumin 32 g/L, globulin 22 g/L, ALT and AST were normal, urea 5.4 mmol/L, creatinine 92 μmol/L, serum β-2 microglobulins 1.77 mg/L; Serum Igs: IgM 19.9 g/L; ESR 98 mm/h
Third cycle; 4/7-16/7/2018	Bortezomib 2.2 mg, dexamethasone 20 mg, and thalidomide tablets 100 mg	CBC: WBC 10.39 × 109/L, Hb 115 g/L, PLT 482 × 109/L; Urinalysis: Urine protein was negative; LFT and RFT: Albumin 38 g/L, globulin 29.8 g/L, urea, creatinine, and serum β-2 microglobulins were normal; Serum Igs: IgM 19.04 g/L; ESR 109 mm/h	CBC: WBC 15.38 × 109/L, neutrophils 80.7%, Hb 116 g/L, PLT 219 × 109/L; LFT and RFT: Albumin 37.8 g/L, globulin 32.7 g/L, urea, creatinine, and serum β-2 microglobulins were normal
Fourth cycle; 2018.1.8	Bortezomib 2.2 mg, dexamethasone 20 mg, and thalidomide 100 mg	CBC: WBC 8.5 × 109/L, Hb 115 g/L, PLT 461 × 109/L, Urinalysis: Urine protein was negative LFT and RFT: Albumin 37.9 g/L, globulin 34.6 g/L, urea, creatinine, and serum β-2 microglobulins were normal; Serum Igs: IgM 20.46 g/L; ESR 98 mm/h

CBC: Complete blood count; LFT: Liver function test; RFT: Renal function test; ESR: Erythrocyte sedimentation rate; TFT: Thyroid function test; CRP: C-reactive protein.